基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
新辅助化疗后浸润性乳腺癌的变化可影响辅助治疗决策
英文原题：Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions.
查看英文原题
Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
NACT 可改变肿瘤特征和生物标志物并影响 OS；因此，应在残留样本上重新评估这些指标，以改进治疗决策。
研究思路结论见上方概要
目的
新辅助化疗（NACT）可改变浸润性乳腺癌（IBC）并影响患者的总生存期（OS）。我们旨在识别NACT后IBC的变化及其与OS的关联。
方法
对86例患者NACT前和NACT后样本的IBC数据进行了评估，并与OS进行关联分析。
结果
NACT后肿瘤的核多形性评分（p=0.025）、核分裂计数（p=0.002）、肿瘤浸润炎性细胞百分比（p=0.016）、原位癌的存在（p=0.001）和淋巴血管侵犯（LVI；p=0.002）、雌激素（p=0.003）、孕激素受体（PR；p=0.019）和Ki67（p=0.003）的表达均发生变化。免疫组化（IHC）分型在26个肿瘤中发生变化（30.2%，p=0.050）。较高的死亡风险与初始肿瘤组织学III级（风险比[HR]，2.94）、高核多形性（HR，2.53）、高Ki67指数（HR，2.47）、NACT后LVI的存在（HR，1.90）、luminal B样分型（HR，2.58）、NACT前（HR，2.26）和NACT后中等核分裂计数（HR，2.12）、NACT前（HR，4.45）和NACT后三阴性IHC分型（HR，4.52）显著相关。另一方面，较低的死亡风险与NACT前（HR，0.35）和NACT后（HR，0.39）雌激素受体阳性，以及NACT前（HR，0.37）和NACT后（HR，0.57）PR阳性显著相关。IHC分型的变化与较长的OS相关（p=0.050）。在多变量分析中，NACT前III级肿瘤以及NACT前和NACT后三阴性IHC分型被证明是较短OS的独立因素。
展开英文摘要原文
PURPOSE
Neoadjuvant chemotherapy (NACT) can change invasive breast carcinomas (IBC) and influence the patients' overall survival time (OS). We aimed to identify IBC changes after NACT and their association with OS.
MATERIALS AND METHODS
IBC data in pre- and post-NACT samples of 86 patients were evaluated and associated with OS.
RESULTS
Post-NACT tumors changed nuclear pleomorphism score (p=0.025); mitotic count (p=0.002); % of tumor-infiltrating inflammatory cells (p=0.016); presence of in situ carcinoma (p=0.001) and lymphovascular invasion (LVI; p=0.002); expression of estrogen (p=0.003), progesterone receptors (PR; p=0.019), and Ki67 (p=0.003). Immunohistochemical (IHC) profile changed in 26 tumors (30.2%, p=0.050). Higher risk of death was significatively associated with initial tumor histological grade III (hazard ratio [HR], 2.94), high nuclear pleomorphism (HR, 2.53), high Ki67 index (HR, 2.47), post-NACT presence of LVI (HR, 1.90), luminal B-like profile (HR, 2.58), pre- (HR, 2.26) and post-NACT intermediate mitotic count (HR, 2.12), pre- (HR, 4.45) and post-NACT triple-negative IHC profile (HR, 4.52). On the other hand, lower risk of death was significative associated with pre- (HR, 0.35) and post-NACT (HR, 0.39) estrogen receptor-positive, and pre- (HR, 0.37) and post-NACT (HR, 0.57) PR-positive. Changes in IHC profile were associated with longer OS (p=0.050). In multivariate analysis, pre-NACT grade III tumors and pre-NACT and post-NACT triple negative IHC profile proved to be independent factors for shorter OS.
CONCLUSION
NACT can change tumor characteristics and biomarkers and impact on OS; therefore, they should be reassessed on residual samples to improve therapeutic decisions.
论文信息
- 作者
- Jaime Dos Santos B、Balabram D、Mara Reis Gomes V、Costa Café de Castro C、Henrique Costa Diniz P、Araújo Buzelin M、Buzelin Nunes C
- 单位
- Laboratory of Mammary Pathology, Department of Anatomical Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.Brazil
- 期刊
- Cancer research and treatment2024 Jan
- 原文标识
- PubMed 37536712 · DOI 10.4143/crt.2023.386
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →